Brilique is an oral antiplatelet treatment for acute coronary syndromes (ACS) in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs). Brilique works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce a patient's risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death. Brilique is the first reversibly-binding oral adenosine diphosphate (ADP) receptor antagonist.
Brilique was developed by AstraZeneca scientists in the late 1990s.For Summary of Product Characteristics and Patient Information Leaflet click this link
Approval ID: 155,827.011
Date of preparation: June 2014